RETRACTED: Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study

Source : Retraction Watch, jointe par DOI. OpenAlex consigne la rétractation dans is_retracted, un booléen sur un espace d'états à au moins quatre valeurs ; il ne peut donc exprimer ni une expression de préoccupation, ni une correction, ni un rétablissement, et les rapporte comme false, ce qui se lit comme « rien à signaler ».

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of all the Authors because an error was detected after publication. On August 25, 2020, eBioMedicine published online findings from a nested cohort study1Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study. Poppe, Tanya et al. EBioMedicine, Volume 59, 102957.Google Scholarwithin the randomised Magnesium sulphate at 30 to <34 weeks’ Gestational age Neuroprotection Trial (MAGENTA). On November 17, 2021, the authors drew our attention to an error that was discovered when the dataset for the parent randomised trial was being finalised. The original MagNUM analysis was conducted blind to treatment group allocation, and an incorrect code was used at the end of that analysis to identify the magnesium sulphate and placebo study groups. Therefore, the group allocations to the magnesium sulphate and placebo study groups in the paper were inadvertently reversed, making the findings, as reported, unreliable. eBioMedicine editors discussed the corrections that were needed in the paper and decided, in accordance with the Committee on Publication Ethics’ guidelines, that because of the extent of the changes necessary, the previous version of the Article should be retracted, and a corrected version be republished after reanalysis and rereview. Today we retract the previous version and republish online the corrected version of the article2Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study. Poppe, Tanya et al. EBioMedicine, DOI: 10.1016/j.ebiom.2022.103923.Google Scholar DOI: 10.1016/j.ebiom.2022.103923 in which the results are unchanged apart from the treatment group assignment. The figures and tables have been corrected accordingly, and the overall message has been modified to convey that antenatal magnesium sulphate prior to preterm birth after 30 weeks’ gestation does not promote white matter development in pathways affecting motor and cognitive function. This previous version of the Article has been added to the appendix in the new version and is marked retracted. The Editors of eBioMedicine eBioMedicine, London, EC2Y 5AS, UK Retraction and republication - effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The MagNUM StudyOn August 25, 2020, eBioMedicine published online findings from a nested cohort study within the randomised Magnesium sulphate at 30 to <34 weeks’ Gestational age Neuroprotection Trial (MAGENTA). On November 17, 2021, the authors drew our attention to an error that was discovered when the dataset for the parent randomised trial was being finalised. The original MagNUM analysis was conducted blind to treatment group allocation, and an incorrect code was used at the end of that analysis to identify the magnesium sulphate and placebo study groups. Full-Text PDF Open Access

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.